GILD Stock Analysis: Gilead Sciences Inc
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In
- Latest close
- $149.05
- 20-day change
- -0.58%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Drug Manufacturers - General
Market context
Gilead Sciences Inc moved -0.58% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $29.4B revenue · $8.5B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Quality is currently the strongest dimension at 5.0/6, while Value is the lowest at 3.3/6. Scores are comparative research signals, not forecasts.